BioDelivery ’ s topical gel for diabetic neuropathy fails in phase IIb trial

BioDelivery Sciences International (NSDQ:BDSI) said today that its clonidine topical gel for pain relief in patients with diabetic neuropathy failed in a phase IIb clinical trial. Raleigh, N.C.-based BioDelivery will halt any further development of the painkiller. In the phase IIb clinical trial, BioDelivery’s topical gel did not demonstrate a statistically significant difference in pain relief compared to a placebo. The company licensed the clonidine topical gel from Arcion Therapeutics to develop and commercialize it in March 2013. Get the full story at our sister site, Drug Delivery Business News. The post BioDelivery’s topical gel for diabetic neuropathy fails in phase IIb trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Diabetes Pain Management Pharmaceuticals BioDelivery Sciences International Source Type: news